Production (Stage)
OS Therapies Incorporated
OSTX
$1.67
$0.042.45%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1,274.93% | 1,418.84% | 631.78% | -26.66% | -8.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 693.32% | 156.39% | 291.74% | -48.54% | -39.87% |
| Operating Income | -693.32% | -156.39% | -291.74% | 48.54% | 39.87% |
| Income Before Tax | -165.72% | -104.23% | -45.58% | 37.83% | 21.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -165.72% | -104.23% | -45.58% | 37.83% | 21.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.72% | -104.23% | -45.58% | 37.83% | 21.01% |
| EBIT | -693.32% | -156.39% | -291.74% | 48.54% | 39.87% |
| EBITDA | -694.09% | -156.27% | -293.83% | 48.56% | 39.93% |
| EPS Basic | 26.66% | -62.81% | 51.85% | 45.26% | -35.24% |
| Normalized Basic EPS | 25.10% | -0.23% | 51.12% | 44.58% | -34.69% |
| EPS Diluted | 26.66% | -62.81% | 51.85% | 45.26% | -35.24% |
| Normalized Diluted EPS | 25.10% | -0.23% | 51.12% | 44.58% | -34.69% |
| Average Basic Shares Outstanding | 254.69% | 103.74% | 197.71% | 12.19% | -41.34% |
| Average Diluted Shares Outstanding | 254.69% | 103.74% | 197.71% | 12.19% | -41.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |